Osivax: Clinical Trials

10 trials sponsored by Osivax, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 6 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Completed 6
Phase 12Completed 2

Follow Osivax: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg
OVX836 480µg, Saline Solution - Influenza
Phase 2CompletedOsivax28912025-09-082026-10-16
A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness
Nasopharyngeal swabs - Influenza
CompletedOsivax1192024-12-132025-06-25
Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836
OVX836 shot - Vaccine-Preventable Diseases, Influenza
Phase 2CompletedOsivax1172024-10-222025-06-06
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers
OVX033, Saline solution - Coronavirus
Phase 1CompletedOsivax482024-01-082026-09-10
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
OVX836 480µg, Fluarix Tetra, Afluria Quad - Influenza
Phase 2CompletedOsivax4782023-05-102024-01-25
Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.
OVX836 480µg, Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra), Placebo - Influenza
Phase 2CompletedOsivax1802022-05-092024-10-31
A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.
Blood samples - Influenza
CompletedOsivax662021-12-012022-07-19
Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.
OVX836-003, Saline solution - Influenza
Phase 2CompletedOsivax2392021-11-152023-08-31
Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years
OVX836, Quadrivalent seasonal influenza vaccine (Influvac TetraTM) - Influenza
Phase 2CompletedOsivax3002019-12-112022-09-22
Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects
OVX836 (Intramuscular), Placebo (Intramuscular), OVX836 (Intranasal) - Influenza
Phase 1CompletedOsivax722018-06-122022-09-22

Conditions studied

Influenza, Human (9)  ·  Coronavirus Infections (1)  ·  Vaccine-Preventable Diseases (1)

Interventions

Saline Solution (3)  ·  Blood Specimen Collection (1)  ·  Influenza Vaccines (1)  ·  Injections, Intramuscular (1)

Countries

Belgium (7)  ·  Australia (2)  ·  France (2)  ·  Finland (1)  ·  Germany (1)

Top investigators

Isabel Leroux-Roels, MD, PhD (3)  ·  Nicola Groth, MD (1)  ·  Odile Launay, MD (1)  ·  Pierre Van Damme, MD, PhD (1)  ·  Ross Aldrich, MBBS (1)

Results publications

PMID 35464450, PMID 37517422, PMID 40573889